China SXT Pharmaceuticals, Inc. (SXTC) stock
SXTCNasdaqPharmaceutical PreparationsFiscal year ends March 31
$3.00+0.27 (+9.89%)
Close on Nov 13, 2026Market cap $2.87MP/E –Yield –
China SXT Pharmaceuticals r&d expenses
Research and development expenses are spending on new products and technology.
For fiscal 2024 it was $184.19K, down 8.2% from the year before.
Annual r&d expenses
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2024 | Mar 31, 2024 | $184.19K | -8.2% |
| FY2023 | Mar 31, 2023 | $200.72K | -45.3% |
| FY2022 | Mar 31, 2022 | $367.01K | – |
See a number that looks wrong?